Get the Stockscreener App
1.89
3.08%
-0.06
After Hours:
1.88
-0.01
-0.53%
Lineage Cell Therapeutics Inc stock is traded at $1.89, with a volume of 889.27K.
It is down -3.08% in the last 24 hours and up +7.39% over the past month.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
See More
Previous Close:
$1.95
Open:
$1.93
24h Volume:
889.27K
Relative Volume:
0.78
Market Cap:
$435.32M
Revenue:
$8.95M
Net Income/Loss:
$-21.49M
P/E Ratio:
-15.75
EPS:
-0.12
Net Cash Flow:
$-29.24M
1W Performance:
+3.85%
1M Performance:
+7.39%
6M Performance:
+53.66%
1Y Performance:
+270.52%
1-Day Range:
$1.865
$1.95
1-Week Range:
$1.82
$1.985
52-Week Range:
$0.3651
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Name
Lineage Cell Therapeutics Inc
Sector
Industry
Phone
510-871-4188
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.89 | 449.14M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-24 | Initiated | Craig Hallum | Buy |
| Nov-02-22 | Initiated | Robert W. Baird | Outperform |
| Jun-14-22 | Initiated | B. Riley Securities | Buy |
| Aug-19-21 | Initiated | Noble Capital Markets | Outperform |
| Mar-31-21 | Initiated | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Stock (LCTX) Latest News
LCTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is now the right time to enter Lineage Cell Therapeutics Inc2025 Top Decliners & Community Shared Stock Ideas - baoquankhu1.vn
Spinal Cord Injury Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development - StreetInsider
LCTX PE Ratio & Valuation, Is LCTX Overvalued - Intellectia AI
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide - PharmiWeb.com
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - Business Wire
Institution Moves: How does Lineage Cell Therapeutics Inc compare to its peersJuly 2025 Momentum & Daily Technical Stock Forecast Reports - baoquankhu1.vn
CEO Moves: What are the future prospects of Lineage Cell Therapeutics IncDip Buying & Expert Curated Trade Setups - baoquankhu1.vn
Revenue Check: Is Lineage Cell Therapeutics Inc a top pick in the sectorWeekly Profit Summary & Weekly Market Pulse Alerts - baoquankhu1.vn
Will Lineage Cell Therapeutics Inc. stock keep raising dividendsMarket Performance Recap & Weekly High Conviction Trade Ideas - mfd.ru
Is Lineage Cell Therapeutics Inc. still a buy after recent gainsM&A Rumor & Reliable Entry Point Alerts - mfd.ru
LCTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Will Lineage Cell Therapeutics Inc. stock hit new highs in YEAR2025 Investor Takeaways & Real-Time Volume Spike Alerts - mfd.ru
Is Lineage Cell Therapeutics Inc. a top pick in the sectorJuly 2025 Fed Impact & High Return Stock Watch Alerts - mfd.ru
Will Lineage Cell Therapeutics Inc. stock maintain dividend yieldMarket Sentiment Summary & Stepwise Trade Signal Implementation - mfd.ru
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from D. Boral Capital - Defense World
D. Boral Capital Reiterates "Buy" Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Cell Therapeutics (LCTX) Receives Consistent Buy Rating from D. Boral Capital | LCTX Stock News - GuruFocus
Lineage Cell says first OpRegen development milestone under Roche pact achieved - MSN
Progress In Research Spring 2024 - Christopher & Dana Reeve Foundation
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Investing News Network
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Benzinga
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Down 3.1%Here's What Happened - MarketBeat
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
Hedge Fund Moves: Can Lineage Cell Therapeutics Inc maintain sales growth2025 Volatility Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Trade Report: Is Lineage Cell Therapeutics Inc a top pick in the sectorRisk Management & Verified Entry Point Detection - baoquankhu1.vn
Market Moves: Is Lineage Cell Therapeutics Inc trading at a discountShare Buyback & Long-Term Safe Investment Plans - baoquankhu1.vn
What are the future prospects of Lineage Cell Therapeutics IncJuly 2025 Snapshot & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Guidance Update: Will Lineage Cell Therapeutics Inc stock hit new highs in YEARMarket Trend Review & Momentum Based Trading Signals - baoquankhu1.vn
Published on: 2026-01-25 17:25:52 - baoquankhu1.vn
Market Overview: Should I average down on Lineage Cell Therapeutics Inc stockEarnings Trend Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Cell Therapy Manufacturing Market Set for Rapid Growth Through - openPR.com
Lineage Takes Delivery of Genetically Engineered iPSC Line with Hypoimmunity Edits from Factor Bioscience - BioInformant
Aug PostEarnings: Can Lineage Cell Therapeutics Inc stock outperform in 2025 bull market - Bộ Nội Vụ
Is Lineage Cell Therapeutics Inc. stock supported by innovation pipelineEarnings Performance Report & Scalable Portfolio Growth Methods - Улправда
CEO Moves: Why Lineage Cell Therapeutics Inc stock remains a top recommendationMarket Movers & Verified Momentum Stock Alerts - Bộ Nội Vụ
What dividend safety score for Lineage Cell Therapeutics Inc. stock2025 Geopolitical Influence & Safe Entry Point Alerts - ulpravda.ru
Aug Outlook: Is Lineage Cell Therapeutics Inc. stock among top earnings playsJuly 2025 Earnings & Comprehensive Market Scan Insights - ulpravda.ru
Institution Moves: How Lineage Cell Therapeutics Inc. stock trades during market volatility2025 Stock Rankings & Daily Stock Trend Reports - ulpravda.ru
Why Lineage Cell Therapeutics Inc. stock is a must watch in 2025July 2025 Breakouts & Safe Capital Growth Plans - Улправда
Is Lineage Cell Therapeutics Inc. stock among top earnings playsJuly 2025 Earnings & Comprehensive Market Scan Insights - ulpravda.ru
What dividend safety rating applies to Lineage Cell Therapeutics Inc. stock2025 Technical Overview & Target Return Focused Picks - Улправда
Can Lineage Cell Therapeutics Inc. stock resist sector downturnsEarnings Trend Report & Precise Swing Trade Alerts - ulpravda.ru
Will Lineage Cell Therapeutics Inc. stock deliver long term returnsTrade Signal Summary & Community Supported Trade Ideas - Улправда
Earnings Miss: Can Lineage Cell Therapeutics Inc. stock resist sector downturnsJuly 2025 Gainers & Reliable Entry Point Trade Alerts - ulpravda.ru
CEO Change: What dividend safety rating applies to Lineage Cell Therapeutics Inc. stock2025 AllTime Highs & Daily Stock Trend Reports - ulpravda.ru
D. Boral Capital Maintains Lineage Cell Therapeutics (LCTX) Buy Recommendation - MSN
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Up 7.6%What's Next? - MarketBeat
2026 world cup injury update tips: Will Lineage Cell Therapeutics Inc. stock benefit from sector rotation2026 world cup usa national team group stage goalkeepers transition play group prediction guide - ulpravda.ru
Lineage Cell Therapeutics (LCTX) Advances Stem Cell Collaboratio - GuruFocus
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience - Business Wire
Lineage Cell Therapeutics Inc Stock (LCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.71%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):